Fibrillary astrocytoma

Summary

Fibrillary astrocytoma (MONDO:0016688) is a disease and 3 clinical trials. Top therapeutic interventions include veliparib. A subtype of diffuse astrocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fibrillary astrocytoma
Mondo ID	MONDO:0016688
Orphanet	251601
DOID	DOID:6726
NCIT	C4322
UMLS	C0334582
MedGen	87270
GARD	0020708
MedDRA	10065889
Is cancer (heuristic)	no

Also known as: fibrillary astrocytic tumours · fibrillary astrocytoma

Data availability: 1 cell line.

Disease family

This is a subtype of diffuse astrocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › astrocytoma (excluding glioblastoma) › low-grade astrocytoma › diffuse astrocytoma › fibrillary astrocytoma

Related subtypes (3): protoplasmic astrocytoma, gemistocytic astrocytoma, diffuse astrocytoma, MYB- or MYBL1-altered

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05956821	PHASE1/PHASE2	RECRUITING	Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
NCT01514201	PHASE1/PHASE2	COMPLETED	Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
NCT05934630	Not specified	TERMINATED	Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VELIPARIB	3	2
CHEMBL4228794	0	1